Kymera Therapeutics
KYMR
Kymera Therapeutics (KYMR) news
Recent news
Kymera Therapeutics, Inc.: Morgan Stanley raises target price to $135 from $119
Morgan Stanley has raised its price target for Kymera Therapeutics, Inc. (NASDAQ: KYMR) to $135 from $119, reflecting a positive outlook on the company’s development pipeline and strategic progress. The adjustment comes amid recent momentum in the stock, which has seen 17.93% increase in share…
AInvest Wire · Aug 6, 2026Kymera Therapeutics has cash runway into '29
AInvest Wire · Aug 5, 2026Kymera Therapeutics has $1.5B in cash as of June 30
AInvest Wire · Aug 5, 2026Kymera Therapeutics Inc: Deutsche Bank initiates coverage with hold rating; target price $120
AInvest Wire · Jul 30, 2026Kymera Therapeutics Inc: Mizuho raises target price to $140 from $120
AInvest Wire · Jul 16, 2026Light Horse does not author, endorse or verify the headlines, and their appearance here is not an endorsement of any view they express.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.